Regulatory & PolicyThe search for a new director of the Centers for Disease Control and Prevention (CDC) is a multifaceted process marked by high expectations, political sensitivity, and urgent public health needs. At the helm of this search is Chris Klomp, a top Department of Health and Human Services official, who has shared insights into the deliberations and challenges faced amidst evolving health threats and governance demands.
Dr. Priya Nandakumar·Mar 20, 2026
Regulatory & PolicyThe FDA stands at a critical crossroads in managing the evolving landscape of individualized therapies for rare diseases. Robert Califf, a former commissioner, underscores how political influence under President Trump seriously compromised the agency's decision-making rigour. Such pressures risk delaying or derailing promising new treatments essential for patients with rare conditions.
Dr. Priya Nandakumar·Mar 20, 2026 
Regulatory & PolicyAs 2026 progresses, the FDA faces both momentum and scrutiny amid dramatic policy shifts affecting biopharma companies. Key issues involve the administration of Regenerative Medicine Advanced Therapy (RMAT) awards and challenges surrounding priority review vouchers, which have historically incentivized innovation but are now being questioned.
Dr. Priya Nandakumar·Mar 19, 2026 
Biopharmaceutical IndustryFollowing the setback of its late-stage drug candidate for pulmonary arterial hypertension, Gossamer Bio initiated major layoffs as part of a cost-saving strategy. The failure of this pivotal trial raises uncertainty about the company's pipeline and financial stability.
Dr. Priya Nandakumar·Mar 19, 2026 
Healthcare InvestmentThe 2026 labor market within the U.S. life sciences sector reflects a dynamic workforce environment where job mobility has become a critical strategy for salary advancement. A new BioSpace report highlights the substantial financial benefits for those switching employers amid ongoing economic pressures and industry recalibration.
Dr. Priya Nandakumar·Mar 19, 2026 
Regulatory & PolicyThis recent cyberattack on Stryker, a major global medical device manufacturer, exposed vulnerabilities in healthcare cybersecurity. The attack caused widespread operational delays, affecting supply chains and posing risks to patient care delivery. Here are six essential points to understand the incident, its implications, and the broader lessons for healthcare organizations.
Dr. Priya Nandakumar·Mar 14, 2026 
AI in Drug DiscoveryWaiv, which originated as the diagnostics division of AI-driven biotech company Owkin, has spun out as an independent entity with substantial new capital to propel its AI-based cancer diagnostic tools. This spinout will enable the company to focus more sharply on advancing precision medicine and clinical applications in oncology.
Dr. Priya Nandakumar·Mar 13, 2026 
Biopharmaceutical IndustryIn a notable development in the biopharma sector, Novo Nordisk and Hims & Hers settled their legal dispute over GLP-1 drugs and agreed on a collaborative partnership. This move underscores the interdependence of traditional pharmaceutical giants and new entrants in the evolving obesity and diabetes treatment landscape.
Dr. Priya Nandakumar·Mar 13, 2026 
AI in Drug DiscoveryThe partnership marks a significant step in integrating agentic AI models into healthcare operations, promising improvements in efficiency, patient care, and financial processes across key industry players.
Dr. Priya Nandakumar·Mar 7, 2026 
Biopharmaceutical IndustryAs biotech companies accelerate clinical programs to achieve competitive and regulatory milestones, workforce adjustments often follow. Alltrna’s recent announcement of laying off over a third of its staff signals a critical phase in its development strategy, underscoring the balancing act between advancing pipelines and maintaining operational efficiency.
Dr. Priya Nandakumar·Mar 6, 2026 
Biopharmaceutical IndustryEli Lilly has launched Lilly Employer Connect, a platform aimed at providing employers with more flexible access to treating obesity through drugs such as Zepbound. While the platform introduces practical options for employers, industry experts note that the progress is largely incremental rather than transformative. This post explores the platform, its features, and the implications for employers and the obesity treatment landscape.
Dr. Priya Nandakumar·Mar 6, 2026 
Biopharmaceutical IndustrySouth Korea has become an increasingly attractive destination for pharmaceutical companies due to its expertise in cutting-edge therapeutic modalities. Roche’s recent pledge underscores this trend, fueling expanded clinical research and investment in the region’s biopharma ecosystem.
Dr. Priya Nandakumar·Mar 5, 2026 